A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to- severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials - PubMed
4 hours ago
- #meta-analysis
- #psoriasis
- #interleukin-23
- Icotrokinra is a novel oral interleukin-23 receptor antagonist peptide for treating moderate-to-severe plaque psoriasis.
- The study included five randomized controlled trials (RCTs) comparing icotrokinra with placebo, involving 1509 patients.
- Icotrokinra significantly improved outcomes such as Investigator's Global Assessment (IGA) scores and Psoriasis Area and Severity Index (PASI) at weeks 4, 8, and 16.
- The treatment also showed efficacy in high-impact, difficult-to-treat areas like the scalp, with significant improvements in scalp-specific IGA scores.
- Safety outcomes indicated no significant difference in serious adverse events or malignancy between icotrokinra and placebo groups.
- The study concludes that icotrokinra has favorable short-term efficacy and an acceptable safety profile, supporting its potential as an oral therapeutic option.
- Long-term studies and comparative trials against current injectable biologic therapies are recommended to further evaluate icotrokinra's role in psoriasis treatment.